Iain S. Mcgregor

Iain S. Mcgregor's AcademicInfluence.com Rankings

Iain S. Mcgregor

Biology

#13276

Historical Rank

Ecology

#617

Historical Rank

biology Degrees

Download Badge

Biology

Iain S. Mcgregor's Degrees

Bachelors Biology University of California, Davis
PhD Ecology University of California, Davis

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Iain S. Mcgregor Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Iain S. Mcgregor's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The effects of predator odors in mammalian prey species: A review of field and laboratory studies (2005) (711)
‘When a rat smells a cat’: the distribution of Fos immunoreactivity in rat brain following exposure to a predatory odor (2001) (480)
Defensive behavior in rats towards predatory odors: a review (2001) (422)
Adolescent Rats Find Repeated Δ9-THC Less Aversive Than Adult Rats but Display Greater Residual Cognitive Deficits and Changes in Hippocampal Protein Expression Following Exposure (2008) (288)
Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats (2004) (280)
Breaking the loop: Oxytocin as a potential treatment for drug addiction (2012) (249)
Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. (1999) (247)
Not all ‘predator odours’ are equal: cat odour but not 2,4,5 trimethylthiazoline (TMT; fox odour) elicits specific defensive behaviours in rats (2002) (237)
A role for oxytocin and 5-HT1A receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (“ecstasy”) (2007) (226)
Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats (2006) (225)
Modulation of anxiety-related behaviours following lesions of the prelimbic or infralimbic cortex in the rat (1997) (214)
Neural Correlates of Cat Odor-Induced Anxiety in Rats: Region-Specific Effects of the Benzodiazepine Midazolam (2004) (214)
Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011 (2013) (210)
The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716 (1999) (202)
Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. (2014) (201)
Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. (2016) (183)
From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long‐term adverse consequences of drug use? (2008) (174)
Aversive effects of the synthetic cannabinoid CP 55,940 in rats (1996) (173)
Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. (2015) (170)
Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats (2011) (167)
A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. (2010) (159)
Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. (2015) (154)
TMT-induced autonomic and behavioral changes and the neural basis of its processing (2005) (150)
Analysis of Cannabis Seizures in NSW, Australia: Cannabis Potency and Cannabinoid Profile (2013) (148)
The cardiovascular and behavioral response to cat odor in rats: unconditioned and conditioned effects 1 1 Published on the World Wide Web on 27 February 2001. (2001) (143)
The direct actions of cannabidiol and 2‐arachidonoyl glycerol at GABAA receptors (2017) (141)
Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro (1999) (135)
Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("ecstasy"). (2001) (134)
Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, and relapse to methamphetamine-seeking behaviour in rats (2010) (132)
Adolescent Oxytocin Exposure Causes Persistent Reductions in Anxiety and Alcohol Consumption and Enhances Sociability in Rats (2011) (128)
Acute Prosocial Effects of Oxytocin and Vasopressin When Given Alone or in Combination with 3,4-Methylenedioxymethamphetamine in Rats: Involvement of the V1A Receptor (2013) (123)
Systemically administered oxytocin decreases methamphetamine activation of the subthalamic nucleus and accumbens core and stimulates oxytocinergic neurons in the hypothalamus (2010) (120)
Increased Anxiety 3 Months after Brief Exposure to MDMA (‘Ecstasy’) in Rats: Association with Altered 5-HT Transporter and Receptor Density (2003) (120)
Cat odor, but not trimethylthiazoline (fox odor), activates accessory olfactory and defense-related brain regions in rats (2008) (113)
(+/-)-3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') increases social interaction in rats. (2000) (112)
Low-Dose Midazolam Attenuates Predatory Odor Avoidance in Rats (1999) (107)
MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks (2000) (107)
Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. (2004) (106)
Habituation of the hiding response to cat odor in rats (Rattus norvegicus). (1999) (106)
A double‐blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome (2014) (105)
Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. (2002) (105)
Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition (2019) (105)
A meta-analysis on the impact of alcohol dependence on short-term resting-state heart rate variability: implications for cardiovascular risk. (2013) (104)
The first CNS-active carborane: A novel P2X7 receptor antagonist with antidepressant activity. (2014) (100)
Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats (2004) (100)
Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes (2003) (95)
Oxytocin directly administered into the nucleus accumbens core or subthalamic nucleus attenuates methamphetamine-induced conditioned place preference (2012) (94)
The distribution of 3,4-methylenedioxymethamphetamine “Ecstasy”-induced c-fos expression in rat brain (1999) (94)
Resilience and reduced c-Fos expression in P2X7 receptor knockout mice exposed to repeated forced swim test (2011) (94)
MDMA (“ecstasy”), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat (2004) (94)
Metabolic effects of neuropeptide Y injections into the paraventricular nucleus of the hypothalamus (1990) (93)
Chronic Fluoxetine Treatment Partly Attenuates the Long-Term Anxiety and Depressive Symptoms Induced by MDMA (‘Ecstasy’) in Rats (2004) (88)
Mephedrone (4‐methylmethcathinone, ‘meow’): acute behavioural effects and distribution of Fos expression in adolescent rats (2012) (87)
Possible neural substrates of beer-craving in rats (1998) (87)
Cannabinoid modulation of rat pup ultrasonic vocalizations. (1996) (87)
High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: Neural consequences and comparison with methamphetamine (2013) (86)
A brief history of oxytocin and its role in modulating psychostimulant effects (2013) (86)
Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions (2019) (85)
Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. (2003) (84)
Longitudinal trends in the dispensing of psychotropic medications in Australia from 2009–2012: Focus on children, adolescents and prescriber specialty (2014) (83)
Differential anxiolytic efficacy of a benzodiazepine on first versus second exposure to a predatory odor in rats (1999) (80)
Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice (2012) (80)
Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey (2018) (80)
A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine (2004) (79)
Heterozygous neuregulin 1 mice display greater baseline and Δ9-tetrahydrocannabinol-induced c-Fos expression (2007) (74)
Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. (2013) (74)
The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse. (2013) (74)
Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat (2005) (73)
Inflammation and Breakdown of the Blood–Retinal Barrier During “Physiological Aging” in the Rat Retina: A Model for CNS Aging (2007) (73)
Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats. (2007) (73)
Oxytocin in the nucleus accumbens core reduces reinstatement of methamphetamine‐seeking behaviour in rats (2016) (73)
Oxytocin inhibits ethanol consumption and ethanol‐induced dopamine release in the nucleus accumbens (2017) (73)
Heart rate variability predicts alcohol craving in alcohol dependent outpatients: further evidence for HRV as a psychophysiological marker of self-regulation. (2013) (73)
The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain (2001) (72)
Rewarding brain stimulation induces only sparse Fos-like immunoreactivity in dopaminergic neurons (1998) (72)
The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. (2011) (71)
Protein expression profile in the striatum of acute methamphetamine-treated rats (2006) (68)
Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the non‐peptide oxytocin receptor agonist WAY 267,464: a biotelemetry study in rats (2014) (68)
Paraventricular hypothalamic CB1 cannabinoid receptors are involved in the feeding stimulatory effects of Δ9-tetrahydrocannabinol (2005) (68)
Oxytocin prevents ethanol actions at δ subunit-containing GABAA receptors and attenuates ethanol-induced motor impairment in rats (2015) (67)
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome. (2019) (66)
Neural activation during cat odor-induced conditioned fear and ‘trial 2’ fear in rats (2005) (66)
The Cannabinoid Receptor Agonist THC Attenuates Weight Loss in a Rodent Model of Activity-Based Anorexia (2011) (65)
The Nonpeptide Oxytocin Receptor Agonist WAY 267,464: Receptor‐Binding Profile, Prosocial Effects and Distribution of c‐Fos Expression in Adolescent Rats (2012) (65)
Defensive responses of Wistar and Sprague-Dawley rats to cat odour and TMT (2006) (63)
Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA (“Ecstasy”) in rats (2004) (63)
Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. (2020) (62)
Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake (2004) (62)
Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial. (2020) (61)
Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. (2003) (61)
Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18) (2020) (60)
Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP 55,940 on behavioral sensitization to cocaine. (1998) (59)
Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ9-THC at Human CB1 and CB2 Receptors (2019) (59)
Mephedrone in Adolescent Rats: Residual Memory Impairment and Acute but Not Lasting 5-HT Depletion (2012) (59)
An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use (2017) (58)
Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats (2018) (58)
Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA (2018) (57)
Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats. (2001) (56)
Medicinal cannabis in Australia, 2016: the Cannabis as Medicine Survey (CAMS‐16) (2018) (56)
Fear, risk assessment, and playfulness in the juvenile rat. (2006) (55)
Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats (2004) (55)
A comparison of Δ9-THC and anandamide induced c-fos expression in the rat forebrain (1998) (54)
The distribution of γ-hydroxybutyrate-induced Fos expression in rat brain: Comparison with baclofen (2009) (54)
MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research. (2007) (52)
Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial. (2019) (52)
Cyclooxygenase-2 in the pathogenesis of murine cerebral malaria. (2004) (51)
Oxytocin and vasopressin modulate the social response to threat: a preclinical study. (2014) (51)
Regional c-Fos and FosB/ΔFosB expression associated with chronic methamphetamine self-administration and methamphetamine-seeking behavior in rats (2012) (51)
On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA (2002) (50)
Topiramate moderately reduces the motivation to consume alcohol and has a marked antidepressant effect in rats. (2007) (49)
Proteomic analysis demonstrates adolescent vulnerability to lasting hippocampal changes following chronic alcohol consumption. (2009) (48)
Intermittent access to beer promotes binge-like drinking in adolescent but not adult Wistar rats. (2009) (47)
Delta9-THC reinstates beer- and sucrose-seeking behaviour in abstinent rats: comparison with midazolam, food deprivation and predator odour. (2005) (47)
The consequences of beer consumption in rats: acute anxiolytic and ataxic effects and withdrawal-induced anxiety (2003) (47)
Predatory threat induces huddling in adolescent rats and residual changes in early adulthood suggestive of increased resilience (2011) (46)
Moderate alcohol intake is related to increased heart rate variability in young adults: implications for health and well-being. (2013) (46)
Rapid quantitation of fluoxetine and norfluoxetine in serum by micro-disc solid-phase extraction with high-performance liquid chromatography-ultraviolet absorbance detection. (2004) (46)
The dopamine receptor antagonist SCH 23390 attenuates feeding induced by Δ9-tetrahydrocannabinol (2004) (45)
Modulation of morphine-induced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716 (2004) (45)
Intranasal oxytocin in the treatment of anorexia nervosa: Randomized controlled trial during re-feeding (2018) (45)
High ambient temperature increases 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”)-induced Fos expression in a region-specific manner (2007) (44)
The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine (2003) (44)
MDMA-induced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635 (2011) (44)
MDMA (‘Ecstasy’) and methamphetamine combined: Order of administration influences hyperthermic and long-term adverse effects in female rats (2005) (44)
Dark Classics in Chemical Neuroscience: Δ9-Tetrahydrocannabinol. (2019) (44)
Adolescent pre‐treatment with oxytocin protects against adult methamphetamine‐seeking behavior in female rats (2016) (43)
Changes in cigarette and alcohol use during cannabis abstinence. (2014) (43)
Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review (2021) (43)
Protein expression profile in the striatum of rats with methamphetamine‐induced behavioral sensitization (2007) (42)
Dopaminergic modulation of rat pup ultrasonic vocalizations. (1999) (42)
Perinatal Exposure to Δ9-Tetrahydrocannabinol Alters Heroin-Induced Place Conditioning and Fos-Immunoreactivity (2006) (42)
Regional differences in naloxone modulation of Δ9-THC induced Fos expression in rat brain (2003) (41)
Beer consumption in rats: the influence of ethanol content, food deprivation, and cocaine. (1999) (41)
Defensive Aggregation (Huddling) in Rattus Norvegicus toward Predator Odor: Individual Differences, Social Buffering Effects and Neural Correlates (2013) (41)
The pro-inflammatory cytokine interferon-gamma is an important driver of neuropathology and behavioural sequelae in experimental pneumococcal meningitis (2014) (41)
Neural correlates of MDMA (“Ecstasy”)-induced social interaction in rats (2009) (40)
Cannabichromene is a cannabinoid CB2 receptor agonist (2018) (40)
Active coping toward predatory stress is associated with lower corticosterone and progesterone plasma levels and decreased methylation in the medial amygdala vasopressin system (2014) (39)
Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive function (2016) (39)
Rats on the grog: novel pharmacotherapies for alcohol craving. (2004) (39)
Access to cannabidiol without a prescription: A cross-country comparison and analysis. (2020) (39)
Using Strawberry Tree WorkbenchMac and Workbench PC software for data acquisition and control in the animal learning laboratory (1996) (37)
Involvement of hypothalamic peptides in the anorectic action of the CB1 receptor antagonist rimonabant (SR 141716) (2009) (37)
Differential behavioural and neurochemical outcomes from chronic paroxetine treatment in adolescent and adult rats: a model of adverse antidepressant effects in human adolescents? (2011) (37)
Metabolic effects of neuropeptide Y injected into the sulcal prefrontal cortex (1990) (36)
Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues. (2017) (36)
Chronic Methamphetamine Self‐Administration Dysregulates Oxytocin Plasma Levels and Oxytocin Receptor Fibre Density in the Nucleus Accumbens Core and Subthalamic Nucleus of the Rat (2016) (36)
Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. (2018) (36)
Defensive behavior (2005) (35)
Aggregation in quads but not pairs of rats exposed to cat odor or bright light (2012) (35)
Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice (2013) (35)
Paraventricular hypothalamic CB(1) cannabinoid receptors are involved in the feeding stimulatory effects of Delta(9)-tetrahydrocannabinol. (2005) (35)
ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice (2016) (34)
Repeated exposure to Δ9-tetrahydrocannabinol alters heroin-induced locomotor sensitisation and Fos-immunoreactivity (2005) (34)
Oxytocin and MDMA (‘Ecstasy’) enhance social reward in rats (2015) (34)
Rats discriminate individual cats by their odor: Possible involvement of the accessory olfactory system (2008) (33)
Automated scoring of novel object recognition in rats (2008) (33)
The role of the vasopressin V1A receptor in oxytocin modulation of methamphetamine primed reinstatement (2018) (33)
Cocaine and heroin (‘speedball’) self-administration: the involvement of nucleus accumbens dopamine and μ-opiate, but not δ-opiate receptors (2005) (33)
Long-lasting FosB/ΔFosB immunoreactivity in the rat brain after repeated cat odor exposure (2009) (32)
Adolescent exposure to oxytocin, but not the selective oxytocin receptor agonist TGOT, increases social behavior and plasma oxytocin in adulthood (2014) (32)
In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA (2017) (31)
Protein expression profile in the amygdala of rats with methamphetamine-induced behavioral sensitization (2008) (31)
Disruptive effects of the prototypical cannabinoid &Dgr;9-tetrahydrocannabinol and the fatty acid amide inhibitor URB-597 on go/no-go auditory discrimination performance and olfactory reversal learning in rats (2011) (31)
Co-administration of THC and MDMA (‘Ecstasy’) Synergistically Disrupts Memory in Rats (2005) (31)
Long-term daily access to alcohol alters dopamine-related synthesis and signaling proteins in the rat striatum (2012) (31)
Preliminary evidence for lowered basal cortisol in a naturalistic sample of methamphetamine polydrug users. (2012) (31)
Exercise increases plasma THC concentrations in regular cannabis users. (2013) (30)
Serotonergic modulation of 3,4-methylenedioxymethamphetamine (MDMA)-elicited reduction of response rate but not rewarding threshold in accumbal self-stimulation (1997) (30)
Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination (2010) (30)
A comparison of delta 9-THC and anandamide induced c-fos expression in the rat forebrain. (1998) (29)
A Nose for Death: Integrating Trophic and Informational Networks for Conservation and Management (2016) (29)
Parameters That Affect Fear Responses in Rodents and How to Use Them for Management (2019) (29)
Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting (2014) (27)
Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research (2020) (27)
Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Actions of Phytocannabinoids or Endocannabinoids on TRPA1 and TRPV1 Channels (2020) (27)
Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures (2018) (27)
Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors (2018) (26)
Neuroadaptations in the Striatal Proteome of the Rat Following Prolonged Excessive Sucrose Intake (2014) (26)
Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats (2004) (25)
Prescribing medicinal cannabis (2020) (24)
CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist (2019) (24)
Detection of Δ9 THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point‐of‐collection testing devices (2019) (24)
Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy (2021) (23)
Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues (2015) (23)
Contrasting effects of dopamine antagonists and frequency reduction on Fos expression induced by lateral hypothalamic stimulation (2002) (22)
Hippocampal protein expression is differentially affected by chronic paroxetine treatment in adolescent and adult rats: a possible mechanism of “paradoxical” antidepressant responses in young persons (2013) (22)
WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action (2015) (22)
Interactions between cannabidiol and Δ9‐tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome (2020) (22)
A long hangover from party drugs: Residual proteomic changes in the hippocampus of rats 8 weeks after γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination (2010) (22)
Intravenous methamphetamine self-administration in rats: Effects of intravenous or intraperitoneal MDMA co-administration (2006) (22)
Reduced sensitivity to MDMA-induced facilitation of social behaviour in MDMA pre-exposed rats (2008) (22)
Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA (2017) (22)
Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: assessment using biotelemetry. (2009) (22)
Cannabinoids increase conditioned ultrasonic vocalisations and cat odour avoidance in rats: strain differences in drug-induced anxiety. (2010) (21)
A novel automated test battery reveals enduring behavioural alterations and cognitive impairments in survivors of murine pneumococcal meningitis (2014) (21)
Chronic repetitive transcranial magnetic stimulation is antidepressant but not anxiolytic in rat models of anxiety and depression (2005) (20)
Regional differences in naloxone modulation of Delta(9)-THC induced Fos expression in rat brain. (2003) (20)
Inhaled vasopressin increases sociability and reduces body temperature and heart rate in rats (2014) (20)
Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial (2020) (20)
The failings of per se limits to detect cannabis-induced driving impairment: Results from a simulated driving study (2021) (20)
Constrasting effects of dopaminergic blockade on MDMA and d-amphetamine conditioned taste aversions (1994) (20)
‘When an old rat smells a cat’: A decline in defense-related, but not accessory olfactory, Fos expression in aged rats (2011) (20)
Metabolic effects obtained from excitatory amino acid stimulation of the sulcal prefrontal cortex (1990) (19)
The Effects of Lithium Carbonate Supplemented with Nitrazepam on Sleep Disturbance during Cannabis Abstinence. (2015) (19)
Preexposure to MDMA (“Ecstasy”) delays acquisition but facilitates MDMA-induced reinstatement of amphetamine self-administration behavior in rats (2004) (19)
Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome. (2021) (19)
Antipsychotic Induced Alteration of Growth and Proteome of Rat Neural Stem Cells (2012) (18)
Regional c-Fos expression induced by peripheral oxytocin administration is prevented by the vasopressin 1A receptor antagonist SR49059 (2016) (18)
Rubbings deposited by cats elicit defensive behavior in rats (2012) (18)
Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. (2020) (18)
Urinary cannabinoid levels during nabiximols (Sativex®)-medicated inpatient cannabis withdrawal (2016) (18)
Comparison of conditioned taste aversions produced by MDMA and d-amphetamine (1993) (18)
Endocannabinoid dysregulation in cognitive and stress-related brain regions in the Nrg1 mouse model of schizophrenia (2017) (17)
Effects of typical (haloperidol) and atypical (risperidone) antipsychotic agents on protein expression in rat neural stem cells (2009) (17)
Stressor-like effects of FG-7142 on medial prefrontal cortex self-stimulation (1990) (17)
Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol (2018) (17)
Metabolomics of Neurotransmitters and Related Metabolites in Post-Mortem Tissue from the Dorsal and Ventral Striatum of Alcoholic Human Brain (2016) (17)
Driving on ice: impaired driving skills in current methamphetamine users (2012) (17)
Medicinal Cannabis for Inflammatory Bowel Disease: A Survey of Perspectives, Experiences, and Current Use in Australian Patients (2020) (17)
Absence of entourage: Terpenoids commonly found in Cannabis sativa do not modulate the functional activity of Δ9-THC at human CB1and CB2 receptors (2019) (16)
Beer promotes high levels of alcohol intake in adolescent and adult alcohol-preferring rats. (2011) (16)
An automated two-choice test of olfactory working memory in the rat: Effect of scopolamine (2000) (16)
Asymmetric suppression of components in binary aldehyde mixtures: behavioral studies in the laboratory rat. (2006) (15)
Metabolic changes associated with ingestion of different macronutrients and different meal sizes in rats (1995) (15)
Prefrontal cortex α 2 adrenoceptors and energy balance (1991) (15)
High ambient temperature increases intravenous methamphetamine self-administration on fixed and progressive ratio schedules in rats (2008) (15)
Antidepressants and adolescent brain development (2011) (15)
Functional genomics of epilepsy-associated mutations in the GABAA receptor subunits reveal that one mutation impairs function and two are catastrophic (2019) (14)
Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV) (2018) (14)
Prefrontal cortex self-stimulation and energy balance. (1991) (14)
Comparative proteomics in the corpus callosal sub-regions of postmortem human brain (2009) (14)
Altered behaviour and cognitive function following combined deletion of Toll-like receptors 2 and 4 in mice (2016) (13)
The Major Plant-derived Cannabinoid Δ9-Tetrahydrocannabinol Promotes Hypertrophy and Macrophage Infiltration in Adipose Tissue (2011) (13)
Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 Survey. (2020) (13)
The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs. (2019) (13)
Cocaine facilitation of prefrontal cortex self-stimulation: a microstructural and pharmacological analysis (2007) (12)
Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies (2020) (12)
Stress-induced changes in respiratory quotient, energy expenditure and locomotor activity in rats: effects of midazolam (1994) (12)
Cannabis reward: biased towards the fairer sex? (2007) (12)
Interleukin-18 deficiency and its long-term behavioural and cognitive impacts in a murine model of pneumococcal meningitis (2014) (12)
MDMA (‘Ecstasy’), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors (2016) (12)
Medical cannabis and driving. (2021) (11)
Evaluation of the Possible Anticonvulsant Effect of Δ9-Tetrahydrocannabinolic Acid in Murine Seizure Models (2020) (11)
Are blood and oral fluid Δ9-tetrahydrocannabinol (THC) and metabolite concentrations related to impairment? A meta-regression analysis (2021) (11)
Footshock stress facilitates self-stimulation of the medial prefrontal cortex but not the lateral hypothalamus in the rat (1989) (11)
Antibody-induced neutrophil depletion prior to the onset of pneumococcal meningitis influences long-term neurological complications in mice (2016) (11)
Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18. (2018) (10)
Cocaine and heroin ('speedball') self-administration: the involvement of nucleus accumbens dopamine and mu-opiate, but not delta-opiate receptors. (2005) (10)
Medicinal cannabis and driving: the intersection of health and road safety policy. (2021) (10)
Sleeplessness (1885) (10)
Medicinal cannabis in the treatment of chronic pain. (2021) (9)
Contrasting effects of stress on medial and sulcal prefrontal cortex self-stimulation (1991) (9)
The effect of cannabidiol on simulated car driving performance: A randomised, double‐blind, placebo‐controlled, crossover, dose‐ranging clinical trial protocol (2020) (9)
The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs. (2018) (9)
Benzodiazepines impair the acquisition and reversal of olfactory go/no-go discriminations in rats. (2007) (9)
Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial (2022) (9)
The kynurenine pathway contributes to long-term neuropsychological changes in experimental pneumococcal meningitis (2014) (9)
Weekly γ-Hydroxybutyrate Exposure Sensitizes Locomotor Hyperactivity to Low-Dose 3,4-Methylenedioxymethamphetamine in Rats (2009) (8)
Determinants of the slow acquisition of medial and sulcal prefrontal cortex self-stimulation: An individual differences approach (1992) (8)
Changes in Respiratory Quotient Elicited in Rats by a Conditioned Stimulus Predicting Food (1998) (8)
Environment-specific conditioning produced by electrical stimulation of the lateral hypothalamus (1989) (7)
Pyrazolo[1,4]diazepines as non-peptidic probes of the oxytocin and vasopressin receptors (2014) (7)
Medicinal Cannabis Prescribing in Australia: An Analysis of Trends Over the First Five Years (2022) (7)
The effect of COVID19 pandemic restrictions on an urban rodent population (2021) (7)
Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial. (2022) (7)
In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018 (2020) (6)
Citalopram and Cannabidiol (2021) (6)
Regional Fos-expression induced by γ-hydroxybutyrate (GHB): Comparison with γ-butyrolactone (GBL) and effects of co-administration of the GABAB antagonist SCH 50911 and putative GHB antagonist NCS-382 (2014) (6)
Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials (2021) (6)
Fasting and exercise increase plasma cannabinoid levels in THC pre-treated rats: an examination of behavioural consequences (2014) (6)
Cannabinoids, insomnia, and other sleep disorders. (2022) (6)
Contrasting regional Fos expression in adolescent and young adult rats following acute administration of the antidepressant paroxetine (2016) (6)
Erratum to: The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain [Brain Research 921 (2001) 240–255] (2002) (6)
Double deficiency of toll-like receptors 2 and 4 alters long-term neurological sequelae in mice cured of pneumococcal meningitis (2019) (6)
Determination of contaminants in artisanal cannabis products used for childhood epilepsy in the Australian community: A sub-analysis of the ‘PELICAN’ study (2021) (5)
Structure-activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. (2022) (5)
NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity? (2021) (5)
A validated method for the simultaneous quantification of CBD, THC, and their metabolites in human plasma, and application to plasma samples from an oral CBD open label trial. (2020) (5)
Behavioral and cognitive data in mice with different tryptophan-metabolizing enzymes knocked out (2016) (5)
Labs make new, dangerous synthetic cannabinoid drugs faster than we can ban them (2015) (5)
Cannabidiol for at risk for psychosis youth: A randomized controlled trial (2021) (5)
Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20) (2022) (4)
Attitudes and Knowledge of Australian Gastroenterologists Around the Use of Medicinal Cannabis for Inflammatory Bowel Disease (2020) (4)
Erratum to: In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA (2017) (4)
Low and high doses of midazolam differentially affect hypoalgesia in rats conditioned to a heat stressor (2005) (4)
Cannabichromene and Δ9-Tetrahydrocannabinolic Acid Identified as Lactate Dehydrogenase-A Inhibitors by in Silico and in Vitro Screening. (2021) (4)
Controllability of prestimulation of the medial prefrontal cortex determines the facilitation of self-stimulation and kindled seizures (1989) (4)
Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome (2022) (4)
Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol (2017) (4)
Oxytocin, Vasopressin and Related Peptides in the Regulation of Behavior: Oxytocin and addiction (2013) (4)
The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence (2022) (3)
Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition. (2022) (3)
P2X7 in Bipolar and Depressive Disorders (2014) (3)
Antipredator responses toward cat fur in wild brown rats tested in a semi-natural environment (2021) (3)
Taste-potentiated odor aversion learning based on amphetamine (1993) (3)
Orally administered cannabidiol does not produce false‐positive tests for Δ9‐tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000 (2021) (3)
Give me a hi-5! An additional version of the h-index (2013) (3)
Oxytocin as an adolescent treatment for methamphetamine addiction after early life stress in male and female rats (2022) (3)
Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting (2014) (3)
Defining Steric Requirements at CB1 and CB2 Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues. (2022) (3)
A nutraceutical product, extracted from Cannabis sativa, modulates voltage-gated sodium channel function (2022) (3)
International conference on memory (ICOM-4), University of New South Wales, Sydney, Australia, 16—21 July 2006 Ecstasy/MDMA and Memory Symposium (2007) (3)
The anticonvulsant zonisamide positively modulates recombinant and native glycine receptors at clinically relevant concentrations (2020) (3)
Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis (2022) (2)
Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (CaV3) Inhibitors. (2022) (2)
Prefrontal cortex alpha 2 adrenoceptors and energy balance. (1991) (2)
The effect of daily aerobic cycling exercise on sleep quality during inpatient cannabis withdrawal: A randomised controlled trial (2020) (2)
Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial (2022) (2)
The anticonvulsant phytocannabinoids CBGVA and CBDVA inhibit recombinant T-type channels (2022) (2)
Sex-specific transcriptomic and epitranscriptomic signatures of PTSD-like fear acquisition (2021) (2)
Cortisol response and psychological distress predict susceptibility to false memories for a trauma film (2016) (2)
An Examination of the Anti-Cancer Properties of Plant Cannabinoids in Preclinical Models of Mesothelioma (2022) (1)
Driving Impairment Following Vaporization of Cannabis-Reply. (2021) (1)
Medicinal cannabis for the treatment of anxiety disorders. (2022) (1)
A Potential Drug-Gene-Drug Interaction Between Cannabidiol, CYP2D6*4, and Fluoxetine: A Case Report. (2022) (1)
The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogues (2018) (1)
Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses (2022) (1)
The impact of Sativex® on cognitive function during treatment for cannabis withdrawal (2014) (1)
A cross-sectional survey exploring the knowledge, experiences and attitudes of Australian pharmacists toward medicinal cannabis (2022) (1)
Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial. (2022) (1)
SPECIAL ISSUE ARTICLE ∆ 9 -THC REINSTATES BEER- AND SUCROSE-SEEKING BEHAVIOUR IN ABSTINENT RATS: COMPARISON WITH MIDAZOLAM, FOOD DEPRIVATION AND PREDATOR ODOUR (2005) (1)
Subject Index Vol. 60, 2009 (2009) (1)
Repeated exposure to a cannabinoid receptor agonist alters subsequent basal and morphine induced fos immunoreactivity (2002) (1)
Excitatory Amino Acids and Their Antagonists (2015) (1)
WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action (2015) (0)
S.12.1 - CANNABINOIDS: A RISK FACTOR FOR A GENETIC MOUSE MODEL OF SCHIZOPHRENIA? (2013) (0)
P-11-15 Induction of immediate early genes following rewarding brain stimulation (1996) (0)
Metabolomics of Neurotransmitters and Related Metabolites in Post-Mortem Tissue from the Dorsal and Ventral Striatum of Alcoholic Human Brain (2016) (0)
Contents Vol. 60, 2009 (2009) (0)
Ecstacy, 'ice' and polydrug use: Long term behavioural effects in rats (2007) (0)
Acute and Long-Term Behavioural Effects of MDMA in Adolescent Rats (2011) (0)
The Effect Of Cannabidiol (CBD) On Exercise Physiology And Bioenergetics: A Randomised Controlled Pilot Trial (2021) (0)
Beyond CBD: Inhibitory effects of lesser studied phytocannabinoids on human voltage-gated sodium channels (2023) (0)
Neural circuitry activated by the unexpected withdrawal of self-administered methamphetamine in rats (2005) (0)
γ-Hydroxybutyrate and 3,4-methylenedioxymethamphetamine combinations: effects on body temperature, behavior, and brain monoamine content in rats (2005) (0)
MEPIRAPIM-derived synthetic cannabinoids inhibit T-type calcium channels with divergent effects on seizures in rodent models of epilepsy (2023) (0)
Methamphetamine or MDMA pretreatment effects subsequent methamphetamine self-administration and MDMA-induced reinstatement in rats (2005) (0)
Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11 (2022) (0)
S33 MDMA, METHAMPHETAMINE AND THEIR COMBINATION: COMPARISON OF LONG-TERM BEHAVIOURAL AND NEURAL EFFECTS IN RATS (2005) (0)
Antipsychotic Induced Alteration of Growth and Proteome of Rat Neural Stem Cells (2012) (0)
Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA, MDMB-4F-BUTINACA and their analogs (2022) (0)
Muscarinic Cholinergic Receptor Agonists and Antagonists (2015) (0)
Mephedrone ('meow'): recent studies using animal models (2011) (0)
Oxytocin and MDMA (‘Ecstasy’) enhance social reward in rats (2015) (0)
Driving on ice: impaired driving skills in current methamphetamine users (2012) (0)
Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition (2019) (0)
Neuroadaptations in the Striatal Proteome of the Rat Following Prolonged Excessive Sucrose Intake (2014) (0)
P.6.a.003 Oxytocin potently antagonises behavioural and neuronal ethanol effects: involvement of GABAA δ subunit-containing receptors (2014) (0)
Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder (2022) (0)
Response to: ‘Cannabis use before safety sensitive work: What delay is prudent?’ (2022) (0)
Cannabis use and non-cancer chronic pain. (2018) (0)
Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa (2021) (0)
The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients (2021) (0)
AN ANIMAL MODEL OF A GENE-ENVIRONMENT INTERACTION: THE ROLE OF NRG1 IN CANNABIS-INDUCED SCHIZOPHRENIA (2010) (0)
Marijuana addiction. (1997) (0)
Laterodorsal tegmentum modulation of nucleus accumbens dopamine release analysed in real time (2001) (0)
-Tetrahydro- cannabinol Promotes Hypertrophy and Macrophage Infi ltration in Adipose Tissue (2012) (0)
Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses (2022) (0)
Advances in addiction neurobiology: decision-making, cannabis and oxytocin (2013) (0)
Results of crossover phase II component of randomized placebo-controlled trial evaluating oral THC/cannabis extract for refractory chemotherapy-induced nausea and vomiting (CINV). (2020) (0)
Fasting and exercise increase plasma cannabinoid levels in THC pre-treated rats: an examination of behavioural consequences (2014) (0)